256 related articles for article (PubMed ID: 24809734)
1. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes.
Gabrusiewicz K; Liu D; Cortes-Santiago N; Hossain MB; Conrad CA; Aldape KD; Fuller GN; Marini FC; Alonso MM; Idoate MA; Gilbert MR; Fueyo J; Gomez-Manzano C
Oncotarget; 2014 Apr; 5(8):2208-20. PubMed ID: 24809734
[TBL] [Abstract][Full Text] [Related]
2. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.
Cortes-Santiago N; Hossain MB; Gabrusiewicz K; Fan X; Gumin J; Marini FC; Alonso MM; Lang F; Yung WK; Fueyo J; Gomez-Manzano C
Oncotarget; 2016 Mar; 7(13):16146-57. PubMed ID: 26910374
[TBL] [Abstract][Full Text] [Related]
3. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
4. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas.
Schneider K; Weyerbrock A; Doostkam S; Plate K; Machein MR
J Neurooncol; 2015 Jan; 121(2):269-78. PubMed ID: 25370707
[TBL] [Abstract][Full Text] [Related]
7. Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
Xu CS; Wang ZF; Dai LM; Chu SH; Gong LL; Yang MH; Li ZQ
J Transl Med; 2014 May; 12():148. PubMed ID: 24884636
[TBL] [Abstract][Full Text] [Related]
8. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy.
Lucio-Eterovic AK; Piao Y; de Groot JF
Clin Cancer Res; 2009 Jul; 15(14):4589-99. PubMed ID: 19567589
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
12. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
13. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
14. Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype.
Liu D; Martin V; Fueyo J; Lee OH; Xu J; Cortes-Santiago N; Alonso MM; Aldape K; Colman H; Gomez-Manzano C
Oncotarget; 2010 Dec; 1(8):700-709. PubMed ID: 21321379
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
16. Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence.
Wick W; Wick A; Weiler M; Weller M
Curr Neurol Neurosci Rep; 2011 Jun; 11(3):305-12. PubMed ID: 21279815
[TBL] [Abstract][Full Text] [Related]
17. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
19. Neutrophils promote the malignant glioma phenotype through S100A4.
Liang J; Piao Y; Holmes L; Fuller GN; Henry V; Tiao N; de Groot JF
Clin Cancer Res; 2014 Jan; 20(1):187-98. PubMed ID: 24240114
[TBL] [Abstract][Full Text] [Related]
20. Extracellular vesicles derived from dendritic cells loaded with VEGF-A siRNA and doxorubicin reduce glioma angiogenesis in vitro.
Shamshiripour P; Rahnama M; Nikoobakht M; Rad VF; Moradi AR; Ahmadvand D
J Control Release; 2024 May; 369():128-145. PubMed ID: 38522817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
